Page last updated: 2024-08-26

bosentan anhydrous and Multiple Sclerosis, Relapsing-Remitting

bosentan anhydrous has been researched along with Multiple Sclerosis, Relapsing-Remitting in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
D'Haeseleer, M; De Keyser, J; Hostenbach, S; Michiels, V; Pauwels, A; Raeymaekers, H; Van Binst, AM; Van Merhaeghen-Wieleman, A; Van Schuerbeek, P	1

Trials

1 trial(s) available for bosentan anhydrous and Multiple Sclerosis, Relapsing-Remitting

Article	Year
Role of cerebral hypoperfusion in multiple sclerosis (ROCHIMS): study protocol for a proof-of-concept randomized controlled trial with bosentan. Trials, 2019, Mar-14, Volume: 20, Issue:1 Topics: Belgium; Bosentan; Cerebrovascular Circulation; Double-Blind Method; Endothelin Receptor Antagonists; Humans; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Proof of Concept Study; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Transcranial	2019

Article

Year

Role of cerebral hypoperfusion in multiple sclerosis (ROCHIMS): study protocol for a proof-of-concept randomized controlled trial with bosentan.

Trials, 2019, Mar-14, Volume: 20, Issue:1

Topics: Belgium; Bosentan; Cerebrovascular Circulation; Double-Blind Method; Endothelin Receptor Antagonists; Humans; Magnetic Resonance Imaging; Multiple Sclerosis, Relapsing-Remitting; Proof of Concept Study; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome; Ultrasonography, Doppler, Transcranial

2019